Agios Pharmaceuticals (NASDAQ:AGIO) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO - Free Report) from a sell rating to a hold rating in a research report released on Saturday.

Several other research firms have also recently weighed in on AGIO. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 target price for the company. Scotiabank decreased their price objective on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a report on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $56.00.

Agios Pharmaceuticals Trading Down 1.4%

AGIO traded down $0.40 during midday trading on Friday, reaching $28.74. The company's stock had a trading volume of 511,844 shares, compared to its average volume of 695,391. The company has a fifty day simple moving average of $29.14 and a 200 day simple moving average of $37.06. The stock has a market cap of $1.66 billion, a P/E ratio of 2.53 and a beta of 0.77. Agios Pharmaceuticals has a twelve month low of $23.42 and a twelve month high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.80) by $0.25. The business had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.86 million. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Sell-side analysts expect that Agios Pharmaceuticals will post -6.85 earnings per share for the current year.

Insider Activity

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the transaction, the director now owns 149,220 shares in the company, valued at approximately $3,864,798. The trade was a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Venturi Wealth Management LLC bought a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at about $33,000. GF Fund Management CO. LTD. acquired a new stake in Agios Pharmaceuticals in the 4th quarter valued at about $39,000. Wingate Wealth Advisors Inc. bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth about $53,000. CWM LLC lifted its position in shares of Agios Pharmaceuticals by 150.2% during the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 996 shares in the last quarter. Finally, Sterling Capital Management LLC grew its stake in shares of Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after purchasing an additional 1,587 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.